

Infusible Platelet Membrane versus Conventional Platelet Concentrate: Benefits and Disadvantages

Nasiri S ^{*1}, Mousavi Hosseini K¹

1. Department of biotechnology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

***Corresponding Author:** Nasiri S, Email: salehnasiri2012@gmail.com

Submitted: 01-05-2013 , Accepted: 29-11-2013

Abstract

Blood transfusion centers are under considerable pressure to produce platelet concentrates with a shelf life limit of 3 to 5 days. Many approaches have been investigated experimentally to produce new hemostatically active platelet products that are capable of long term storage. In this article infusible platelet membrane will be explained as a platelet substitute versus conventional liquid-stored platelet concentrates with regard to their benefits and disadvantages in transfusion medicine. This review shows that lyophilized infusible platelet membrane as a platelet substitute might offer many important benefits over common platelet concentrates with few disadvantages. Infusible platelet membrane may have efficacy, safety and acceptable tolerability without thrombogenicity, immunogenicity or toxicity. The other main benefits of this product are improved shelf life, ease of storage, high-precision dose calculation, easy reformulation, reduced viral and bacterial load, decreased refractoriness to platelet transfusion, reduced contaminating red and white blood cells, reduced side effects due to removal of undesirable effects of intracellular and extracellular proinflammatory mediators and removal of platelet-derived microparticles as a source of CD40/CD40L ligands, which can enhance post-transfusion reactions, achieving hemostatic response without increasing the circulating platelet count, not being removed from circulation by immune mechanisms or sepsis and not requiring blood typing. In spite of these benefits, there are still some difficulties in demonstrating its efficacy, short-term circulation and hemostatic function. Therefore, further human clinical studies will be needed to fully define the exact role of infusible platelet membrane in the management of patients with thrombocytopenia.

Keywords: Infusible platelet membrane, platelet, substitute, platelet concentrates, side effects.

Introduction

Platelet concentrates are usually stored in blood transfusion centers for 3 to 5 days, then they are discarded; therefore, blood transfusion centers are under considerable pressure to produce platelet concentrates for transfusion. Many approaches have been explored experimentally to produce novel hemostatically active platelet products that are capable of long-term storage¹⁻⁴. These include: frozen platelet storage, liquid cold (4°C) storage, rehydrated lyophilized platelets, and platelet membrane microparticles. Platelets play a dual role in hemostasis. First, they show adhesion and aggregation properties at sites of vascular lesion^{5,6}. Second, the exposure of anionic phospholipids on the surface of activated platelets acts as a catalytic

site for the initiation of coagulation cascade that will strengthen initial hemostatic plug formation^{7,8}. This review summarizes previous in vitro, pre-clinical and clinical studies of infusible platelet membrane (IPM) versus conventional platelet concentrates in order to compare their benefits and disadvantages.

Conventional liquid-stored platelet concentrates

Platelet concentrates for transfusion into bleeding thrombocytopenic patients have been available for routine clinical use for 5 decades. Transfusion adverse reactions such as fever, rigors, and more rarely, life-threatening acute injury, occur to 30% of platelet transfusion recipients, which is

significantly higher than red cell transfusions⁹. Currently platelet concentrates can be transfused up to five days after preparation, but there is a concern that platelet efficacy and safety may decline during storage due to platelet activation which increases over time. Other issues that might be involved in this "storage lesion" are platelet surface P-selectin¹⁰ and platelet-derived soluble mediators, histamine¹¹, CD40 ligand (CD40L)¹², regulated on activation normal T cell expressed and secreted protein (RANTES), platelet factor 4 (CXCR4), transforming growth factor- β and CXCL8 (IL-8)¹⁰. Besides enhancing platelet activation, increased soluble CD40L levels have been associated with an increased risk of allergic and febrile reactions in platelet transfusion recipients, as well as lung injury^{13,14}. A recent report has indicated that platelet-derived microparticles which carried the sCD40L, accumulated in the platelet concentrates during the 5 days of storage, which might induce transfusion adverse events such as a transfusion related acute lung injury (TRALI)¹⁵. Once platelets become activated to release these mediators, they may well be less effective in hemostasis upon transfusion. In addition to changes in soluble mediators, the entire platelet proteome has also been shown to change over time in storage, which can lead to their functional decline^{16,17}. Refractoriness, the inability to increase platelet counts post-transfusion due to ABO-incompatibility¹⁸⁻²⁰, exposed Human Leukocyte Antigen (HLA)-A, and the presence of B proteins on the platelet surface are other common complications^{21,22}. In addition, transfused platelets can contribute to inflammation and organ injury by the release of α -granule mediators and cytokines²³⁻²⁶. Moreover, platelet transfusions may be associated with thrombosis, contributing to common conditions such as acute coronary syndrome, ischemic stroke, transient ischemic attack and deep vein thrombosis²⁷⁻³⁰. It may be concluded that during storage for transfusion, platelets experience decreased efficacy/viability, while levels of prothrombotic and proinflammatory soluble mediators and microparticles increase. This trend could be due to activation and platelet death within the unit. On the other hand, the method of platelet preparation can play a significant role in platelet activation due to effects of centrifugation speed on platelet aggregation activity^{31,32}.

Bacterial contamination occurs in about 1/3000

platelet units and can lead to sepsis in 1 out of 6 contaminated products³³, which appears to represent a greater risk than that associated with other blood products. This is in large part because platelet concentrates must be kept at a temperature of $22^{\circ} \pm 2^{\circ}\text{C}$ during storage; therefore, unlike red blood cells bacterial growth is not inhibited by low temperature storage.

Infusible platelet membrane

Previous in vitro experiments have confirmed that lysed platelets shorten prolonged coagulation times^{34,35}. Preliminary studies in animals showed that disintegrated platelets are toxic and may not be effective^{36,37}. When large amounts of these platelets were given intravenously over a short period of time, severe circulatory and respiratory effects were regularly observed in irradiated thrombocytopenic dogs³⁸ and this also had a marked effect on prothrombin consumption. It was interpreted that these side effects are caused mainly by serotonin when they were markedly reduced when dogs were given a serotonin analogue for 4 days before transfusions³⁹. On the other hand, some clinical observations in thrombocytopenic patients showed that platelets may have hemostatic effect, even if they are not intact and improve hemostasis with no evidence of serious toxicity or thrombosis^{37,40}. Due to side effects problems, this sort of investigations was abandoned for nearly three decades because these materials produced considerable distress in experimental animals³⁸ until experiments in thrombocytopenic rabbits with infusible platelet membrane indicated preclinical evidence of their hemostatic efficacy without significant morbidity⁴¹. Methods for storage of platelets in liquid state or by cryopreservation yield many lysed platelets and membrane vesicles^{42,43}. Transfusion of these infusible platelet membrane vesicles into rabbits at various levels of thrombocytopenia has shown that hemostasis can be achieved without an increase in circulating platelet count and that platelet membrane vesicles induce reductions in bleeding times^{41,44-46}. In contrast, some other studies have concluded that blood bank platelets must be intact and circulate for a hemostatic response to be achieved and that the indication of a successful platelet transfusion is an increase in circulating platelet count⁴⁷⁻⁵⁰. One company, Cypress Bioscience Incorporated (San Diego, CA, USA)

has manufactured a microparticulate, known as IPM Cyplex™ from outdated blood bank human platelets by lysis and differential centrifugation and treatment to inactivate blood-borne viruses⁴⁴. IPM has been successfully administrated in normal human volunteers and thrombocytopenic patients in phase I and II clinical trials. The phase II trials have been performed among bleeding refractory thrombocytopenic patients and have provided some indication of improvement (cessation of bleeding) in some patients³. Results of phase III clinical trials are awaited. It should be noted that, this product has not yet been licensed by the FDA because of the difficulties in demonstrating efficacy. The efficacy of this product in platelet transfusion cases that have developed antibodies to HLA and platelet antigens is under investigation. It is difficult to determine the effects of any platelet substitutes in thrombocytopenic patients since they typically have other conditions associated with a bleeding tendency. Furthermore, evaluation of efficacy of a platelet substitute is difficult because major bleeding due to platelet dysfunction is rare⁵¹. Perfusion methods such as the one explained by Baumgartner⁵² have facilitated the investigation of mechanisms involved in hemostatic function of platelet concentrates. Different researchers have used these perfusion techniques to evaluate the impact of different storage conditions on platelet reactivity⁵³⁻⁵⁷. The results of perfusion studies have shown that platelet fragments or nonviable platelets (IPM)⁵⁸⁻⁶¹ and synthetic phospholipids⁶² promote a procoagulant activity that can be proved on the surface of damaged cells. A preliminary clinical study of lyophilized platelet material in patients with secondary thrombocytopenia has indicated no toxicity or thromboembolic sequelae⁴⁰. A study on thrombogenicity of IPM by Wessler et al.⁶³ has indicated that IPM is not thrombogenic⁴⁴. In normal human volunteers, infusions of IPM were well tolerated and had no effect on biochemical or coagulation parameters and no evidence of immunogenicity was reported³. As general, little has been published on the effects of manufacturing processes on intrinsic platelet antigens and neoantigen formation for platelet products and substitutes. The risk of infection with IPM product is very low due to the applied pasteurization treatment in IPM⁶⁴ as well as plasma products⁶⁵⁻⁶⁶.

Infusion of large amounts of disintegrated platelets over a short period of time has caused severe circulatory and respiratory effects in irradiated dogs due to the presence of serotonin³⁹. Similarly, infusion of stored and frozen platelets (-15°C up to 6 weeks) without cryoprotectant to severely thrombocytopenic patients has led to transient elevation of the blood pressure and local constriction due to the presence of serotonin, with no evidence of serious toxicity or thrombosis³⁷.

With respect to hemostatic effectiveness, significant reduction of bleeding time has been reported by infusion of stored platelet membrane vesicles (for up to 6 months at -65°C) to thrombocytopenic rabbits³⁹. Different studies have shown that IPM (2 mg/kg) can shorten the prolonged bleeding time in thrombocytopenic rabbits for at least 6 h after infusion^{44,45}; by 24 h this hemostatic effect was no longer detectable. Administration of IPM at 4 mg/kg has been shown to change bleeding time from 900 to 450 seconds in thrombocytopenic rabbits⁵¹. In another study, patients with platelet counts less than 50×10^9 /L and mucosal hemorrhage received either a single dose of IPM (ranging from 2 to 6 mg/kg) or standard platelet concentrate. Improvement or complete cessation of bleeding was reported in 17 of 26 (65%) treated with IPM and 3 of 5 (60%) who received conventional platelet concentrates⁴¹. In one investigation, normal human volunteers received IPM at a maximum dose of 6 mg/kg over 30 to 40 minutes. They received aspirin orally before the infusion of IPM and the volunteers with the prolonged bleeding time were selected. The administration of IPM in these volunteers shortened the bleeding time and none of patients appeared to develop antibodies to IPM as determined by flow cytometry³. In another study, 6 of 8 thrombocytopenic patients receiving 3 or 6 mg/kg of IPM had a shortening of at least one of 2 or 3 bleeding times performed after infusion; however, shorter bleeding times were also observed in 2 of 2 patients after infusion of placebo⁶⁷. In another report, a randomized, dose-ranging study was performed to determine the safety and efficacy of IPM on patients aged 18 to 70 years who had moderate active bleeding with platelet count less than 50×10^9 /L. Ten patients received IPM (6 mg/kg) and 2 received random-donor platelets. In 7 of 10 (70%) patients treated with IPM and in both

patients who received random-donor platelets, bleeding decreased or stopped. When evaluating the refractoriness to platelet transfusion, 2 of 4 (50%) patients who were refractory to platelets responded to IPM, while 5 of 6 (83%) patients who were not refractory to platelets did so. Furthermore, one refractory patient who did not respond to IPM had an obvious increment in platelet count after receiving a platelet transfusion and it was concluded that IPM may decrease refractoriness to platelet transfusion³.

Discussion

It seems that IPM as a platelet substitute might demonstrate efficacy, safety, acceptable tolerability without thrombogenicity, immunogenicity or toxicity. In spite of challenges in demonstrating its efficacy, investigations should continue to provide maximal clinical benefits with minimal risk of complications^{68,69}.

The proposed advantages of IPM over products containing intact platelets include:

- Improved shelf life, ease of storage and use.
- Reduced viral and bacterial load.
- Reduced expression of human leukocyte antigen (HLA) class 1 antigens.
- Being prepared from outdated platelets so can be more easily accessible for mass procurement.
- May decrease refractoriness to platelet transfusion.
- Reduced contaminating red and white blood cells which can promote antibody formation against them.
- Reduced side effects due to removal of undesirable effects of intracellular and extracellular proinflammatory mediators such as serotonin, cytokines and chemokines.
- Reduced side effects due to removal of platelet-derived microparticles, as a source of CD40/CD40L ligands, which can enhance post-transfusion reactions.
- Achieving hemostatic response without increasing circulating platelet count which is the main part of a successful platelet transfusion.
- Not being removed from circulation by immune mechanisms or sepsis.
- Not being entrapped in the spleen and microvasculature by virtue of their smaller size.
- Having a high-precision dose calculation and easy

reformulation.

- Not requiring blood typing, so it can be infused immediately and for patient with all blood types.
- May reduce side effect of transfusion-associated circulatory overload (TACO) due to lower volume administration.

The disadvantages of IPM over platelet concentrates include:

- Short-term circulation and hemostatic function.
- Not being more effective in comparison with fresh intact platelet units in ordinary doses.
- More difficult to quantify its effects in thrombocytopenic patients who typically have other conditions associated with a bleeding tendency.
- Not suitable for rapid administration.

Conclusion

It may be deduced that the main challenge for IPM as a platelet substitute is its efficiency in human clinical trial studies. However, it may be realized that not all platelet properties have to be covered by a platelet substitute. Such a substitute may be able to replace certain aspects of platelet function and may be appropriate in specific clinical situations. However, further human clinical studies are required to more fully define the exact role of platelet membranes as a drug in the management of patients with thrombocytopenia.

References

1. Lee DH, Blajchman MA. Novel treatment modalities: new platelet preparations and substitutes. *Br J Haematol*. 2001;114(3):496-505.
2. Lee DH, Blajchman MA. Novel platelet products and substitutes. *Transfus Med Rev*. 1998;12(3):175-87.
3. Alving BM, Reid TJ, Frattoloni JC, Finlayson JS. Frozen platelets and platelet substitutes in transfusion medicine. *Transfusion*. 1997;37(8):866-76.
4. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. *J Thromb Haemost*. 2003;1(7):1637-41.
5. Boon GD. An overview of hemostasis. *Toxicol Pathol*. 1993;21:170-9.
6. Ruggeri ZN. Platelet Adhesion under Flow. *Microcirculation*. 2009;16(1):58-83.
7. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of

- exposure. *Blood Rev.* 1991;5(3):146-54.
8. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. *Biochim Biophys Acta.* 1983;736(1):57-66.
 9. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. *Transfusion.* 1993;33(10):794-7.
 10. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. *Transfusion.* 2006;46(5):800-10.
 11. Konca K, Tiftik EN, Aslan G, Kanik A, Yalçın A. The effect of cromoglycate on time-dependent histamine and serotonin concentrations in stored blood products. *Transfus Apher Sci.* 2006;34(2):193-8.
 12. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. *J Thromb Haemost.* 2007;5(4):788-96.
 13. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. *Blood.* 2006;108(7):2455-62.
 14. Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. *Transfusion.* 2006;46(10):1813-21.
 15. Xie RF, Hu P, Li W, Ren YN, Yang J, Yang YM, et al. The effect of platelet-derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst. *Vox Sang.* 2013 Oct 21. [Epub ahead of print].
 16. Thon JN, Schubert P, Duguay M, Serrano K, Lin S, Kast J, et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. *Transfusion.* 2008;48(3):425-35.
 17. Springer DL, Miller JH, Spinelli SL, Pasa-Tolic L, Purvine SO, Daly DS, et al. Platelet proteome changes associated with diabetes and during platelet storage for transfusion. *J Proteome Res.* 2009; 8(5):2261-72.
 18. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. *Blood.* 2005;105(10):4106-14.
 19. Pavenski K, Warkentin TE, Shen H, Liu Y, Heddle NM. Post-transfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. *Transfusion.* 2010;50(7):1552-60.
 20. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. *Eur J Haematol.* 1993;50(2):110-7.
 21. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. *Transfusion.* 2000;40(12):1446-56.
 22. Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? *Transfusion.* 2008;48(2):221-7.
 23. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. *Cell Immunol.* 2005; 238(1):1-9.
 24. Davi G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med.* 2007;357(24):2482-94.
 25. Mause SF, von Hundelshausen P, Zerneck A, Koenen RR and Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. *Arterioscler Thromb Vasc Biol.* 2005;25(7):1512-8.
 26. McNicol A and Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. *Cardiovasc Hematol Disord Drug Targets.* 2008; 8(2):99-117.
 27. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. *Circ J.* 2010;74(4):597-607.
 28. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch Intern Med.* 2008;168(21):2377-81.
 29. de Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. *Anesth Analg.* 2008;106(1):32-44.
 30. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. *Transfusion.* 2004;44(8):1143-48.
 31. Nasiri S, Mousavi Hosseini K. Effects of centrifugation speed on platelet aggregation activity. *Koomesh.*

- 2014;15(2):250-4. (Article in Persian).
32. Merolla M, Nardi MA, Berger JS. Centrifugation speed affects light transmission aggregometry. *Int J Lab Hematol*. 2012;34(1):81-5.
33. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. *Hematology Am Soc Hematol Educ Program*. 2003:575-89.
34. Bode AP, Eick L. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood. *Am J Pathol*. 1989;91(4):430-4.
35. Bode AP, Castellani WJ, Hodges EA, Yelberton S. The effects of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT). *Thromb Hemost*. 1991;66(2):213-7.
36. Fliender TM, Sorensen DK, Bond VP, Cronkite EP, Jackson DP, Adamik E. Comparative effectiveness of fresh and lyophilized platelets in controlling irradiation hemorrhage in the rat. *Proc Soc Exp Biol Med*. 1958;99(3):731-3.
37. Klein E, Toch R, Farber S, Freeman G, Fiorentino R. Hemostasis in thrombocytopenic bleeding following infusion of stored, frozen platelets. *Blood*. 1956;11(8):693-9.
38. Hjort PF, Perman V and Cronkite EP. Fresh, disintegrated platelets in radiation thrombocytopenia: Correction of prothrombin consumption without correction of bleeding. *Proceedings of the Society of Experimental Biology and Medicine*. 1959;102:31-5.
39. Wooley DW and Edelman PM. Displacement of serotonin from tissues by a specific antimetabolite. *Science*. 1958;127(3293):281-2.
40. Klein E, Farber S, Djerassi I, Toch R, Freeman G, Arnold P. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. *The Journal of Pediatrics*. 1956;49(5):517-22.
41. McGill M, Fugman DA, Vittorio N, Darrow C. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits. *Journal of Laboratory and Clinical Medicine*. 1987;109(2):127-33.
42. Spector JJ, Flor WJ, Valeri CR. Ultrastructural alterations and phagocytic function of cryopreserved platelets. *Transfusion*. 1979;19(3):307-12.
43. Bode AP, Orton SM, Frye MJ, Udis BJ. Vesiculation of platelets during in vitro aging. *Blood*. 1991;77(4):887-95.
44. Chao FC, Kim BK, Houranieh AM, Liang FH, Konrad MW, Swisher SN, et al. Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. *Transfusion*. 1996;36(6):536-42.
45. Nasiri S, Heidari M, Rivandi S. Evaluation of hemostatic effectiveness of infusible platelet membrane in rabbits as a potential substitute for platelet transfusion. *Journal of Drug Delivery and Therapeutics*. 2012;2(5):1-3.
46. Nasiri S, Heidari M, Rivandi S. Infusible platelet membranes improve hemostasis in thrombocytopenic rabbits: studies with two different injection doses. *International Journal of Pharmaceutical Sciences Research*. 2012;3(12):4895-8.
47. Baldini M, Costea N, Dameshek W. The viability of stored human platelets. *Blood*. 1960;16:1669-92.
48. Harker LA, Roskos L, Cheung E. Effective and efficient platelet transfusion strategies that maintain hemostatic protection. *Transfusion*. 1998;38(7):619-21.
49. Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. *Thromb Res*. 2011;127(4):287-91.
50. Flisberg P, Rundgren M, Engström M. The effects of platelet transfusions evaluated using rotational thromboelastometry. *Anesth Analg*. 2009;108(5):1430-2.
51. Vostal JG, Reid TJ, Mondoro TH. Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes. *Transfusion*. 2000;40(6):742-50.
52. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. *Microvasc Res*. 1973;5(2):167-79.
53. McGill M and Brindley DC. Effects of storage on platelet reactivity to arterial subendothelium during blood flow. *J Lab Clin Med*. 1979; 94(2):370-80.
54. Escolar G, Hagert-Whiting K, Bravo ML, White JG. Interaction of long-term stored platelets with vascular subendothelium. *J Lab Clin Med*. 1987;109(2):147-54.
55. Mazzara R, Escolar G, Garrido M, Pereira A, Castillo R, Ordinas A. Evaluation of the transfusion effectiveness of various platelet concentrates by means of an in vitro perfusion technique. *Transfusion*. 1991;31(4):308-12.
56. Escolar G, Mazzara R, White JG, Castillo R, Ordinas A. Contribution of perfusion techniques to the

- evaluation of the hemostatic effectiveness of platelet concentrates. *Blood Cells*. 1992;18(3):403-15.
57. Owens M, Holme S, Heaton A, Sawyer S, Cardinali S. Post-transfusion recovery of function of 5-day stored platelet concentrates. *Br J Haematol*. 1992; 80(4):539-44.
 58. Hernandez MR, Bozzo J, Mazzara R, Ordinas A, Escolar G. Platelet concentrates promote procoagulant activity: evidence from experimental studies using a perfusion technique. *Transfusion*. 1995;35(8):660-5.
 59. Galan AM, Bozzo J, Hernández MR, Pino M, Reverter JC, Mazzara R, et al. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions. *Transfusion*. 2000;40(9):1074-80.
 60. Alemany M, Hernandez MR, Bozzo J, Galan AM, Reverter JC, Mazzara R, et al. In vitro evaluation of the hemostatic effectiveness of non viable platelet preparations: Studies with frozen-thawed, sonicated or lyophilized platelets. *Vox Sang*. 1997;73(1):36-42.
 61. Ahmadzadeh N, Yari F, Amirizadeh N, Khorramizadeh MR. Production and characterization of liquid-stored and lyophilized reconstituted human infusible platelet membranes. *Int J Lab Hematol*. 2011;33(6):586-92.
 62. Galan AM, Hernandez MR, Bozzo J, Reverter JC, Estelrich J, Roy T, et al. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: studies under flow conditions. *Transfusion*. 1998;38(11-12):1004-10.
 63. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. *J Appl Physiol*. 1959;14:943-6.
 64. Nasiri S, Heidari M. Application of sodium caprylate as a stabilizer during pasteurization of infusible platelet membrane and evaluation of its effectiveness by turbidity assay. *International Journal of Analytical, Pharmaceutical and Biomedical Sciences*. 2012;1(2):34-6.
 65. Rezvan H, Nasiri S, Mousavi K: Inactivation of poliovirus type-I and HSV -I in human coagulation factor VII concentrate by pasteurization. *Arch Iran Med*. 2001;4(1):10-13.
 66. Nasiri S, Sharifi Z. Evaluation of Viral Inactivation in Suspension Containing 20% Albumin by Pasteurization Method. *Iranian Journal of Virology*. 2010;4(1):34-6.
 67. Goodnough LT, Kolodziej M, Ehlenbeck C. A phase I study of safety and efficacy for infusible platelet membrane in patients. *Blood*. 1995;86 (Suppl.),610a.
 68. Nasiri S. Platelet membranes versus intact platelets: Feasibility as a potential platelet substitute. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2013; 2(3):763-81.
 69. Nasiri S. Infusible platelet membrane as a platelet substitute for transfusion: an overview. *Blood Transfusion*. 2013; 11(3):337-42.